Ana Sayfa Biyoteknoloji Fresenius Submits Application to EMA for Adalimumab Biosimilar

Fresenius Submits Application to EMA for Adalimumab Biosimilar

Pelfilfrastim
Fresenius Kabi biyobenzerlerine aldığı onaylarla dikkat çekiyor

Fresenius SE & Co. KGaA (FRE.XE) said Monday that it has submitted a biosimilar marketing authorization application to the European Medicines Agency for adalimumab.

Fresenius’s drug is a biosimilar candidate of AbbVie Inc.’s (ABBV) Humira, which is used to treat chronic inflammatory autoimmune conditions such as arthritis and Crohn’s disease.

Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com

(END) Dow Jones Newswires